Evidence map›Paper›PMID 33978302›Full record

ArticleAngewandte Chemie (International ed. in English)2021

Enantioselective Total Synthesis and Structural Revision of Dysiherbol A.

Julian Baars, Isabelle Grimm, Dirk Blunk, Jörg-Martin Neudörfl, Hans-Günther Schmalz

Open access · greenAbstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Enantioselective Total Synthesis and Structural Revision of Dysiherbol A.Angewandte Chemie (International ed. in English) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Julian BaarsUniversity of Cologne, Department of Chemistry, Greinstrasse 4, 50939, Cologne, Germany.
Isabelle GrimmUniversity of Cologne, Department of Chemistry, Greinstrasse 4, 50939, Cologne, Germany.
Dirk BlunkUniversity of Cologne, Department of Chemistry, Greinstrasse 4, 50939, Cologne, Germany.
Jörg-Martin NeudörflUniversity of Cologne, Department of Chemistry, Greinstrasse 4, 50939, Cologne, Germany.
Hans-Günther SchmalzUniversity of Cologne, Department of Chemistry, Greinstrasse 4, 50939, Cologne, Germany.ORCID 0000-0003-0489-1827
TH Köln - University of Applied Sciences · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 12-step total synthesis of the natural product dysiherbol A, a strongly anti-inflammatory and anti-tumor avarane meroterpene isolated from the marine sponge Dysidea sp., was elaborated. As key steps, the synthesis features an enantioselective Cu-catalyzed 1,4-addition/enolate-trapping opening move, an Au-catalyzed double cyclization to build up the tetracyclic core-carbon skeleton, and a late installation of the C5-bridgehead methyl group via proton-induced cyclopropane opening associated with spontaneous cyclic ether formation. The obtained pentacyclic compound (corresponding to an anhydride of the originally suggested structure for dysiherbol A) showed identical spectroscopic data as the natural product, but an opposite molecular rotation. CD-spectroscopic measurements finally confirmed that both the constitution and the absolute configuration of the originally proposed structure of (+)-dysiherbol A need to be revised.

Indexed as

Biological ProductsMolecular ConformationSesquiterpenesStereoisomerismBiological Productsdysiherbol ASesquiterpenescyclizationenantioselectivitygold catalysisnatural productsrearrangement

Identifiers

PMID33978302
PMCPMC8251742
OpenAlexW3160574241

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.